- Oral presentation
- Open Access
Analysis of survival data from trials with non-proportional hazards: an empirical comparison of methods
© Royston et al; licensee BioMed Central Ltd. 2013
- Published: 29 November 2013
- Failure Time
- Summary Measure
- Acceleration Factor
- Empirical Comparison
- Method Accounting
Non-proportional hazards are increasingly observed in publications of large trials. However, to use or not to use a method accounting for non-proportional hazards may be a difficult decision, in the absence of appraisals of existing methods and the uncertainty in whether results provide different or more insights into the clinical questions.
We analyse survival data reconstructed from two trials publications which reported extreme non-proportional hazards (with respective p-values as 9.19E-13 and 1.344E-24 in non-PH Grambsch-Thernau test). We use the Cox proportional hazards model, flexible parametric model and accelerated failure time model to estimate the time-independent hazard ratio, between-arm difference in restricted mean survival time (RMST) and acceleration factor as respective summary treatment effect measures. Estimation of the latter two measures does not require PH. We also analyse the hazard ratio and difference in RMST as time-dependent effects.
In this empirical study, the three summary measures produce broadly similar results on the evidence against the null hypothesis. Both the Cox model and the flexible model are able to incorporate time-dependent treatment effects to account for non-proportional hazards. Flexible parametric models support plotting of the time-dependent hazard ratio and time-dependent difference in RMST, which provides useful insights into how the treatment effect measure may change with time.
Although p-values for the three summary measures have similar influence on the statistical significance of treatment effects, using the difference in RMST as the summary measure emphasizes the often-neglected time-horizon and allows more intuitive interpretation of the magnitude of treatment effects.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.